Phase III SWOG S1203: Idarubicin + High-Dose Cytarabine ± Vorinostat vs Standard Therapy in Newly Diagnosed AML

December 3-6, 2016; San Diego, California
In this phase III trial, idarubicin plus high-dose cytarabine with or without vorinostat did not show superiority to 7 + 3 regimen in untreated AML patients 60 years of age or younger.
Format: Microsoft PowerPoint (.ppt)
File Size: 476 KB
Released: December 8, 2016


This activity is supported by educational grants from
Celgene Corporation
Merck & Co., Inc.
Seattle Genetics

Related Content

CCO printable treatment algorithm and toxicity management table to help optimize care of your patients with follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Released: September 30, 2020

Jacob D. Soumerai, MD, on how managing patients with CLL has evolved over the first 6 months of the COVID-19 pandemic, from Clinical Care Options (CCO)

person default Jacob D. Soumerai, MD Released: September 30, 2020

Commentary from David Marks, MD, PhD, on considerations for using blinatumomab vs inotuzumab ozogamicin in the treatment of relapsed/refractory ALL, from CCO

Released: September 30, 2020

Expert commentary from Danielle M. Brander, MD, on the implications of MRD evaluation in patients with CLL, as reported by Clinical Care Options (CCO)

Danielle Brander, MD Released: September 29, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.